Clinical Trial Intelligence

Is Overall Survival Still the Endpoint Anchor in European Phase III Lung Cancer Trials?

Across 150 included European Phase III lung cancer trials from 2024–2026, overall survival does not appear to be disappearing from endpoint strategy. The stronger signal is endpoint layering: 70.9% of recorded primary endpoint structures were single-primary designs, while 29.1% used dual-primary architecture, often combining faster disease-control readouts with survival anchoring.

150
Included trials
70.9%
Single-primary endpoint structure
29.1%
Dual-primary endpoint structure
58.3%
Dual-primary share in 2026

How Much of the Evidence Base Comes From Each Year?

The 150-trial evidence base is weighted toward 2024, which contributes 66.0% of included trials. 2025 contributes 25.3%, while 2026 contributes 8.7%, making 2026 useful as an early signal but not as a stand-alone trend base.

Included Trials by Authorization Year
2024
66.0%
2025
25.3%
2026
8.7%
Endpoint Strategy in European Phase III Lung Cancer Trials
Conclusion

The report should be interpreted as a combined 2024–2026 evidence base. The 2026 signal is directionally useful, but the strongest conclusions come from the full 150-trial cohort.

Are Primary Endpoints Mostly Single or Dual?

Single-primary endpoint architecture remains the dominant pattern at 70.9%, while dual-primary endpoint architecture accounts for 29.1%. This shows that most late-stage lung cancer trials still concentrate the formal primary endpoint claim, but nearly one-third use a more complex endpoint structure.

Single vs Dual Primary Endpoint Architecture
Single primary
70.9%
Dual primary
29.1%
Endpoint Strategy in European Phase III Lung Cancer Trials
Conclusion

The practical takeaway is that endpoint strategy is not uniformly simplified. A 29.1% dual-primary share is large enough that feasibility, statistics, medical writing, and regulatory teams should treat endpoint hierarchy as a core planning risk.

Is Dual-Primary Architecture Becoming More Visible?

Dual-primary architecture was 23.8% in 2024, 32.0% in 2025, and 58.3% in 2026. The 2026 figure should be read cautiously because the 2026 cohort is smaller, but the direction is consistent with more visible endpoint layering in recent submissions.

Dual-Primary Endpoint Share by Year
2024
23.8%
2025
32.0%
2026
58.3%
Endpoint Strategy in European Phase III Lung Cancer Trials
Conclusion

The numeric signal is not that OS is being abandoned, but that sponsors may increasingly need two formal efficacy anchors: one to support earlier disease-control interpretation and one to preserve survival credibility.

Is Overall Survival Being Replaced?

No clear replacement signal is visible. OS appears across all 3 authorization years and across 3 endpoint positions: primary, co-primary, and secondary. The dataset points to repositioning of OS within a broader endpoint hierarchy rather than removal of OS from late-stage lung cancer strategy.

Observed OS Positioning in Endpoint Hierarchy
1
Primary OS

OS remains visible as a direct primary endpoint strategy.

2
Co-primary OS

OS is also paired with endpoints such as PFS in dual-primary designs.

3
Secondary OS

OS frequently supports faster primary endpoints as a secondary survival anchor.

Endpoint Strategy in European Phase III Lung Cancer Trials
Conclusion

The answer is no: OS is not clearly being replaced. It is being combined with faster endpoints, especially PFS, DFS, EFS, and response-based measures, to balance earlier readout pressure with survival credibility.

Executive Interpretation

The 150-trial dataset shows that European Phase III lung cancer endpoint strategy is not moving toward a simple OS-versus-PFS split. Single-primary endpoint designs still dominate at 70.9%, but the 29.1% dual-primary share is large enough to matter operationally. The 2026 signal, where dual-primary architecture reaches 58.3%, suggests endpoint layering may become more visible in newer submissions.

Bottom Line

Overall survival remains an endpoint anchor, but increasingly as part of a hierarchy rather than as the only endpoint story. For clinical development, medical writing, regulatory, and CRO teams, the planning question is not whether OS is present, but how OS is positioned against faster endpoints that drive readout timing and trial competitiveness.